NCT04216290
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 215 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 17, 2026 Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria shortened, about 14 words
- Secondary endpoints revised (8)
- Study description revised
- Site details revised at 17 of 216 sites
- Notable Enrollment reduced: 95 → 11 participants
- Primary completion moved earlier from Jun 30, 2026 to Feb 4, 2026
- Study completion pushed from Jun 30, 2026 to May 19, 2027
- Study Status, Contacts/Locationsv209
- Minor Study sites revised (216)v208
- Minor Study sites revised (216)v206
Show 29 earlier versionsHide 29 earlier versions
- Minor Study sites revised (216)v205
- Minor Study sites revised (216)v204
- Minor Study sites: 217 to 216v203
- Minor Study sites revised (217)v200
- Minor Study sites revised (217)v199
- Minor Study sites: 218 to 217v198
- Minor Study sites revised (218)v197
- Minor Study sites revised (218)v196
- Minor Site details revised at 1 of 218 sitesv195
- Notable Eligibility criteria expanded, about 22 words
- Secondary endpoints: details revised at 8 of 8 entries
- Study description expanded, about 28 words
- Study title shortened, about 1 word
- Minor Study sites revised (218)v191
- Minor Study sites revised (218)v190
- Minor Study sites revised (218)v189
- Minor Study sites revised (218)v188
- Minor Study sites revised (218)v186
- Minor Study sites revised (218)v184
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 218 of 218 sites
- Notable Start date: Aug 25, 2020 to Mar 17, 2021
- Site details revised at 1 of 218 sites
- Minor Site details revised at 1 of 218 sitesv179
- Minor Site details revised at 1 of 218 sitesv178
- Minor Study sites: 217 to 218v176
- Minor Site details revised at 1 of 217 sitesv175
- Minor Study sites: 216 to 217v174
- Minor Site details revised at 1 of 216 sitesv173
- Minor Study sites revised (216)v171
- Minor Site details revised at 2 of 216 sitesv170
- Minor Site details revised at 2 of 216 sitesv169
- Minor Site details revised at 1 of 216 sitesv167
Notable Eligibility criteria shortened, about 55 wordsv166 Show 4 more changesShow less
- Enrollment target: 102 to 95
- Interventions: Cisplatin (Drug), Durvalumab (Biological), Fluorouracil (Drug), Gemcitabine Hydrochloride (Drug), Mitomycin (Drug), Patient Observation… to Biopsy of Bladder (Procedure), Biospecimen Collection (Procedure), Cisplatin (Drug), Computed Tomography (Procedure), Cystoscopy…
- Study description expanded, about 101 words
- Site details revised at 1 of 216 sites
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
Procedures: Biopsy of Bladder, Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging
Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Mitomycin
Biologicals: Durvalumab
Other: Patient Observation
Radiation: Radiation Therapy
Sites
216 sites in 1 country